Kangbaida (Sichuan) Biotechnology Co. Ltd. has synthesized pyrrolidine derivatives acting as Toll-like receptor 7 (TLR7) and/or (TLR8) antagonists reported to be useful for the treatment of autoimmune disease.
Rednvia Co. Ltd. has disclosed alkaline phosphatase tissue-nonspecific isozyme (TNAP) inhibitors reported to be useful for the treatment of ectopic calcification.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by synaptic dysfunction, neuronal loss and the accumulation of amyloid plaques and neurofibrillary tangles, ultimately leading to cognitive decline. Despite significant research efforts, no existing treatment has proven effective enough to stop or reverse the progression of the disease.
The mitochondria play a crucial multifunctional role in the progression of malignant tumors. Therefore, researchers are working to understand the link between mitochondrial DNA mutations and abnormalities in mitochondrial-associated proteins and cancer development and progression.
Erasca Inc. has obtained IND clearance by the FDA for ERAS-4001, an oral selective pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant solid tumors.
Radiopharm Theranostics Ltd. has reported preclinical data from studies with the Lu177-B7H3-monoclonal antibody (mAb) RV-01 demonstrating favorable biodistribution and showing that RV-01 maintained high tumor uptake.
LIN28 is a family of RNA-binding proteins that regulate stem cell biology and pluripotency and are involved in oncogenesis through the interaction with tumor suppressor microRNA let-7. The expression of LIN28 leads to the loss of function of let-7, leading to tumorigenesis, and has been tied to tumor aggressiveness and poor survival in children with brain tumors.
Sanofi SA has exercised its option to exclusively license Nurix Therapeutics Inc.’s STAT6 program, including the drug development candidate NX-3911, an oral, highly selective STAT6 degrader.
Recludix Pharma Inc. has nominated a lead development candidate, REX-8756, an oral, selective and reversible small-molecule inhibitor of STAT6, and completed GLP toxicology studies for the compound. REX-8756 has potential for patients with type 2 immune-related inflammatory diseases.
The systemic virotherapy strategy involves not only the direct delivery of therapeutic payloads encoded by viruses to tumors, but also the modification of the tumor microenvironment, aiming to target both primary and metastatic lesions. At the ongoing American Society of Clinical Oncology (ASCO) meeting, researchers from Calidi Biotherapeutics Inc. reported the development of a novel approach using a selected and engineered tumor-selective strain of vaccinia virus.
RSS
